Healthcare Distribution Alliance (HDA) President and CEO Chester “Chip” Davis, Jr., released the following statement regarding the Drug Enforcement Administration’s (DEA) proposed rule on suspicious orders.
Healthcare Distribution Alliance (HDA) President and CEO Chester “Chip” Davis, Jr., released the following statement regarding the Drug Enforcement Administration’s (DEA) proposed rule on suspicious orders.
A report published by the Healthcare Distribution Alliance (HDA) Research Foundation and Deloitte Consulting LLP found that during the first 90 days of the COVID-19 pandemic, the biopharmaceutical finished goods industry quickly adapted and adjusted to deliver medicines safely and efficiently to patients, with only minimal disruptions.
In response to the Food and Drug Administration’s (FDA) decision to extend enforcement discretion related to certain Drug Supply Chain Security Act requirements, the Healthcare Distribution Alliance (HDA) released the following statement.
HDA’s Pharmaceutical Cargo Security Coalition recognized three outstanding supply chain security professionals today through the annual PCSC Awards.
The Healthcare Distribution Alliance (HDA) today released policy principles reaffirming the pharmaceutical distribution industry’s commitment to ensuring — in partnership with federal and state governments — the safe and efficient distribution of COVID-19 vaccines once they are approved by the Food and Drug Administration.
John Parker
(703) 885-0216
Farah Simonett
(703) 885-0269